Method for detecting platelet stress condition by using kit
The detection of platelet EAAT2 membrane protein through flow cytometry combined with a kit has solved the problem of cumbersome and inaccurate detection in the prior art, and achieved rapid and accurate monitoring of platelet stress. It is suitable for clinical applications and improved detection efficiency and sensitivity .
Patent Information
- Application Number
- CN202410969495.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art methods for detecting platelet EAAT2 membrane proteins are cumbersome, inflexible and highly disturbing, resulting in inaccurate detection results and difficult to promote in clinical laboratories.
The platelet suspension was incubated with EAAT2 polyclonal antibody, CD61-directly coupled PE fluorescent dye and flow fluorescent secondary antibody by using flow cytometry combined with the test method, and the samples were fixed by paraformaldehyde, using flow cytometry. Detect specific signals to confirm platelet stress status.
It realizes rapid and accurate detection of platelet stress, reduces sample interference, improves detection efficiency and sensitivity, is suitable for clinical applications, and can monitor blood tests such as stroke and neurodegenerative diseases in real time, providing richer references for disease diagnosis and prediction .
Smart Images

Figure CN118962145A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the field of medical testing technology, and in particular to a method for detecting platelet stress status using a kit. Background Art
[0002] Platelets are anucleate membrane-structured cells, belonging to non-traditional cells, which are susceptible to the stimulation of the extracellular microenvironment and undergo different degrees of skeleton reorganization. The phenotypic changes of platelet cells can reflect the stress state of the human body to a certain extent. The platelet's EAAT2 (Excitatory Amino Acid Transporter 2) dominates the platelet's glutamate uptake and is mainly distributed on the platelet membrane and the α-granule membrane of the platelet. When the real-time state of the platelet changes, the distribution of the EAAT2 membrane protein will change significantly with the reorganization of the platelet skeleton. The existing technology commonly uses immunoelectron microscopy (Immunoelectron microscopy, IEM) and immunofluorescence (Immunofluorescence, IF) to detect EAAT2 membrane protein, but these two technologies are very cumbersome in the processing of blood samples. Not only is the detection cycle long, but the experimental scheme is also inflexible, and overly cumbersome or excessive intervention operations may have a great impact on the detection results of EAAT2 membrane protein, and the detection results are not accurate enough, and are not suitable for promotion in clinical laboratories. Summary of the invention The purpose of the present application is to at least partially overcome the deficiencies of the prior art and to provide a method for detecting platelet stress using a kit with high timeliness and simple operation.
[0003] In order to achieve the above technical objectives, the technical solutions adopted in this application are as follows: The present application provides a method for detecting platelet stress using a kit, wherein the kit comprises a platelet diluent, an EAAT2 polyclonal primary antibody, a flow cytometry fluorescent secondary antibody, an EAAT2 isotype control, a monoclonal antibody directly coupled to a PE fluorescent dye with CD61, and 1% paraformaldehyde; the EAAT2 polyclonal primary antibody recognizes at least one of the amino acid sequences shown in SEQ ID No. 1 to SEQ ID No. 5; The detection method includes the following steps: preparing a platelet suspension using the platelet diluent; The platelet suspension is incubated with the EAAT2 polyclonal primary antibody, the monoclonal antibody directly coupled to the CD61 PE fluorescent dye, and the flow cytometry fluorescent secondary antibody in sequence; Adding the paraformaldehyde to fix the sample to form a sample to be detected; Detecting specific signals of the sample by flow cytometry; Statistical analysis of the specific signals confirmed the stress status of the samples.
[0004] Optionally, the platelet diluent comprises 10 mM HEPES, 135-145 mM NaCl, 2.6-2.8 mM KCl, 11-12 mM NaHCO3, 1-2 mM MgCl2, 0.4-0.5 mM Na2HPO4, 5-6 mM glucose, 0.2-0.4% bovine serum albumin, and has a pH of pH7.2-pH7.4.
[0005] Further optionally, the flow cytometry fluorescent secondary antibody includes a colorimetric marker derived from a goat anti-rabbit antibody that specifically recognizes the EAAT2 polyclonal primary antibody; the isotype control of the EAAT2 is a rabbit-derived IgG ISOtype.
[0006] Furthermore, the kit also includes other platelet-related marker antibodies, including specific antibodies for CD41, CD42b, CD62P, CD63 and / or PAC-1.
[0007] Specifically, the platelet suspension is incubated with the EAAT2 polyclonal primary antibody, the monoclonal antibody directly coupled to the CD61 PE fluorescent dye, and the flow cytometry fluorescent secondary antibody in sequence, comprising: First, the platelet suspension is incubated at room temperature and away from light for 15 to 30 minutes using the EAAT2 polyclonal primary antibody and the monoclonal antibody directly coupled to the CD61 PE fluorescent dye; The platelet suspension is then incubated in the dark at room temperature for 15 to 20 minutes using the flow cytometry fluorescent secondary antibody.
[0008] Further optionally, the kit also includes a platelet stress regulator, which includes an activator, inhibitor, interfering agent or anti-interfering agent for the platelets; before incubating the platelet suspension with the EAAT2 polyclonal primary antibody, the monoclonal antibody directly coupled to the CD61 PE fluorescent dye and the flow cytometry fluorescent secondary antibody in sequence, the stress regulator is added according to the needs of statistical analysis.
[0009] Optionally, the stress modulator includes glutamate, arachidonic acid, adenosine diphosphate, collagen, adrenaline, thrombin, thrombin receptor activating enzyme or lipopolysaccharide as activators, excitatory amino acid transporter inhibitors as inhibitors, and inhibitors for preventing fibrin polymerization and thus blood clot formation.
[0010] Alternatively, the platelet suspension is prepared by: Freshly collected blood was anticoagulated; Centrifuge at 200 g for 10-15 min at room temperature; After the plasma is harvested, it is allowed to stand for 30 minutes to obtain platelet-rich plasma; 5 μL of the platelet-rich plasma was taken and added to 95 μL of the platelet diluent to prepare a platelet suspension.
[0011] Furthermore, the specific signal-associated excitatory amino acid transporter 2 is associated with platelets, and the cell analysis results of flow cytometry are statistically analyzed to confirm the cell phenotype of platelets under different stress conditions.
[0012] Compared with the prior art, this application has the following advantages: (1) The method of the present application utilizes the advantages of flow cytometry and can analyze individual platelets, thereby analyzing the overall stress of the platelets of the individual corresponding to the blood sample from a statistical perspective, providing reference data for subsequent identification and prediction of the patient's condition; and the reagents used in the entire flow cytometry are reasonably proportioned to form a kit, which is conducive to the unification of the detection method; (2) The method of the present application utilizes the association between platelets and EAAT2 membrane protein, providing a blood test method that can detect stroke, neurodegenerative diseases, etc. in real time, thereby increasing the possibility of clinical promotion; (3) The sample preparation process of the method of the present application is simple, the interference with platelets is reduced to the lowest possible level, and the state of cell stress is maintained as much as possible, which is conducive to reflecting more realistic test results, and also improves the test efficiency, which is conducive to application in clinical testing; (4) The samples prepared by the method of the present application can simulate stress or drug intervention scenarios by adding stress regulators, providing more abundant reference data for subsequent identification and prediction of the patient's condition, which is conducive to improving the accuracy of judgment and prediction. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 The four different platelet subpopulations counted by the method of detecting platelet stress status using a kit in the present application mainly show the distribution of platelets in the sample in four areas.
[0014] Figure 2 This is a schematic diagram of the expression pattern of platelet EAAT2 membrane protein statistically analyzed using the method of detecting platelet stress status using the kit of the present application, mainly showing the detection effect diagram of the negative isotype control and the positive result.
[0015] Figure 3The expression characteristics of platelet EAAT2 membrane protein in healthy people are statistically analyzed using the method of detecting platelet stress status using the kit of the present application, wherein A shows the basal state, B shows the activated state, and C shows the reactivated state after inhibitor treatment.
[0016] Figure 4 The results of detecting specific samples using the method of the present application for detecting platelet stress status using a kit are shown, mainly showing the expression characteristics of platelet EAAT2 membrane protein in patients with AIS accompanied by hemorrhagic transformation.
[0017] Figure 5 The method of using the kit in the present application to detect platelet stress status is used to distinguish the detection results of CD61 low-fluorescence platelet subpopulation and CD61 high-fluorescence platelet subpopulation.
[0018] Figure 6 This is a graph showing the Annexin V expression results of four platelet phenotypes jointly labeled with EAAT2-CD61 using the method of the present application for detecting platelet stress status using a kit.
[0019] Figure 7 The results of the method of detecting platelet stress status using a kit in the present application confirmed that the expression of EAAT2 membrane protein is closely correlated with the increased expression of platelet PAC-1. DETAILED DESCRIPTION
[0020] The present application is further described in detail below in conjunction with the accompanying drawings and specific implementation methods.
[0021] Previous studies have found that platelet activation requires the enhanced uptake of glutamate by excitatory aminoacid transporters (EAATs); under high-concentration glutamate incubation conditions and during platelet activation, the expression of EAAT2 membrane protein (the main subtype of platelet EAATs) can be seen to be upregulated to varying degrees, suggesting that EAAT2 membrane protein is closely related to the response and activation mechanism of platelets, and that EAAT2 membrane protein is a biomarker with significant clinical translational value.
[0022] EAATs are high-affinity glutamate transporters that simultaneously transport three Na + and an H + Then, a K +. Relying on its special molecular transport mechanism, glutamate can form a transmembrane concentration gradient of up to one million times on both sides of the cell membrane at the resting membrane potential level of the cell, and can continuously perform transport within a wide concentration range. Given that EAAT2 is the main subtype of EAATs protein on platelets, they must be correctly located on the cell membrane to exert the biological activity of transporting glutamate. Therefore, if the expression changes of EAAT2 membrane protein on platelets can be dynamically monitored, it will not only help analyze the uptake capacity of individual platelets, but also help understand the real-time activation status of platelets, and even evaluate the response intensity of platelets to target activators. The present application intends to provide a set of flow cytometry detection kits that can specifically identify platelet EAAT2 (Excitatory AminoAcid Transporter 2) membrane proteins by selecting flow cytometry antibodies that specifically recognize the extracellular segment of EAAT2 membrane proteins.
[0023] Existing technologies use other techniques to detect EAAT2 membrane proteins in peripheral blood cells (including platelets), such as Immunoelectron microscopy (IEM), immunofluorescence (IF), and Western blot combined with surface biotin labeling. Immunoelectron microscopy (IEM) is a technique that combines electron microscopy and immunological principles. Researchers can observe the location and distribution of EAAT2 proteins in cells by using antibodies labeled with gold particles or other substances with high electron density in samples. Immunofluorescence (IF) technology can be used to detect EAAT2 proteins in cells or tissues. During the experiment, the sample must be fixed, sliced and stained first, and then antibodies labeled with fluorescent dyes are used to bind to EAAT2 proteins. The fluorescent signal is observed under a fluorescence microscope to determine the location and distribution of EAAT2 proteins. Western blot (WB) technology is often used to study protein expression levels and the presence of specific proteins in cells or tissues. Western blot technology combined with surface biotin labeling can improve the sensitivity and accuracy of detecting EAAT2 protein located on the cell membrane surface by combining surface biotin-labeled antibodies with EAAT2 protein and then using surface biotin ligase and fluorescein for detection. However, the above-mentioned technologies have failed to quantify or visualize the expression changes of platelet EAAT2 protein at the membrane protein level. In contrast, the EAAT2 membrane protein detection method based on flow cytometry can not only clearly present the expression of platelet EAAT2 membrane protein, but also can be used to distinguish various phenotypes related to platelet activation and evaluate the degree of platelet heterogeneity.
[0024] The advantages of immunoelectron microscopy (IEM) are high sensitivity and high resolution. It can detect very low concentrations of proteins and determine their location at the cellular or subcellular level. However, its disadvantages are that it requires professional equipment and technology, is complex and time-consuming to operate, has strict requirements for sample processing, and is prone to protein inactivation or structural damage. The advantages of immunofluorescence (IF) are high sensitivity and specificity. It can be used to detect the distribution and localization of proteins in cells. The operation is relatively simple and the results can be obtained quickly. However, its disadvantages are that it is not accurate enough for quantitative analysis and may be interfered by background fluorescence. It requires professional equipment and more complex technical optimization. Simple Western blot technology cannot specifically detect EAAT2 proteins located on the cell membrane surface, so it is only suitable for analyzing the total EAAT2 protein level in platelet homogenates. Theoretically, Western blot technology combined with surface biotin labeling combines the quantitative advantages of Western blot with the high sensitivity of surface biotin labeling, and can be used to accurately detect the expression levels of membrane proteins and their differences in different samples. However, its operation is complicated and requires additional reagents and equipment support. The results obtained are relatively poor in specificity, and are especially not suitable for highly sensitive cells such as platelets that are easily stimulated.
[0025] In general, the above-mentioned existing technologies not only require expensive professional equipment, such as electron microscopes and laser confocal microscopes, but also require long and tedious antibody incubation and / or light fixation steps. These processes have a great stimulation on platelets, and the exogenous stimulation caused by the tedious operation can easily significantly change the expression level of platelet EAAT2 membrane protein, causing the results to deviate seriously from the true level. In addition, due to the long detection cycle of these technologies, the lack of flexibility in experimental schemes, and the lack of supporting commercial detection kits, they are not suitable for promotion and application in clinical laboratories, but only for research laboratories.
[0026] Flow cytometry has significant advantages in analyzing the number, size, morphology, surface molecule expression and activity of platelets. It is easy to operate, including centrifugal separation of platelet-rich plasma, staining, fixation, and on-machine detection. It has little stimulation to platelets, and the experimental results can be obtained within 2 hours, which can better reflect the real-time characteristics of the subject's platelets. Therefore, in order to detect the dynamic expression of platelet EAAT2 membrane protein, this application selects a polyclonal flow antibody that can specifically recognize the extracellular segment of EAAT2 protein, and develops a set of flow detection kits suitable for in vitro quantitative detection of platelet EAAT2 membrane protein. The experimental results show that the kit and detection method of this application are sensitive and efficient, and the results are stable and reliable. In addition, based on the simple EAAT2 membrane protein detection scheme, multiple staining can be combined with other platelet marker antibodies, and then different control groups or intervention groups can be added according to different experimental purposes to achieve personalized and accurate diagnosis and analysis of the subject's platelets, and finally achieve the purpose of providing clinical multi-dimensional information on the subject's platelets.
[0027] The method of detecting platelet stress status using a kit of the present application, wherein the kit comprises a platelet diluent, an EAAT2 polyclonal primary antibody, a flow cytometry fluorescent secondary antibody, an EAAT2 isotype control, a monoclonal antibody directly coupled to a PE fluorescent dye of CD61, and 1% paraformaldehyde; the EAAT2 polyclonal primary antibody recognizes at least one of the amino acid sequences shown in SEQ ID No. 1 to SEQ ID No. 5; The detection method includes the following steps: preparing a platelet suspension using the platelet diluent; The platelet suspension is incubated with the EAAT2 polyclonal primary antibody, the monoclonal antibody directly coupled to the CD61 PE fluorescent dye, and the flow cytometry fluorescent secondary antibody in sequence; Adding the paraformaldehyde to fix the sample to form a sample to be detected; Detecting specific signals of the sample by flow cytometry; Statistical analysis of the specific signals confirmed the stress status of the samples.
[0028] More specifically, the essential components of the kit of the present invention include: ① Platelet diluent, which is a modified HT buffer: 10 mM HEPES, 135-145 mM NaCl, 2.6-2.8 mM KCl, 11-12 mM NaHCO3, 1-2 mM MgCl2, 0.4-0.5 mM Na2HPO4, 5-6 mM glucose, 0.2-0.4% bovine serum albumin, pH 7.2-pH 7.4; ②EAAT2 polyclonal primary antibody and flow cytometry fluorescent secondary antibody thereof; wherein, the EAAT2 polyclonal primary antibody can specifically recognize the extracellular epitope fragments of platelets, and the extracellular epitope fragments of platelets are amino acid sequences shown in SEQ ID No.1 to SEQ ID No.5, and the EAAT2 polyclonal primary antibody can be prepared according to at least one of the extracellular epitope fragments; correspondingly, the flow cytometry fluorescent secondary antibody includes a fluorescent colorimetric marker that can be excited in a flow cytometer, and also includes a segment that can be specifically recognized by the EAAT2 polyclonal primary antibody. The flow cytometry fluorescent secondary antibody in this embodiment is derived from a goat anti-rabbit polyclonal antibody; ③EAAT2 isotype control, used as a negative control, using rabbit IgG ISOtype; ④CD61-PE, i.e., monoclonal antibody of CD61 directly coupled to PE fluorescent dye, and may also include other platelet-related marker antibodies, ⑤ Fixative: This embodiment of the present application uses 1% paraformaldehyde.
[0029] Among them, the EAAT2 / GLT-1 antibody is a mouse polyclonal antibody that can recognize the EAAT2 membrane protein of human, monkey, rat and mouse cells. The recognition site is located in the extracellular segment of the EAAT2 membrane protein, such as at least one of the amino acid sequences shown in SEQ ID No.1~SEQ ID No.5; its secondary antibody is Anti-rabbit IgG (H+L); the isotype control of the primary antibody is rabbit IgGISOtype. CD61 in CD61-PE is also called GPIIIa, which can form a GPIIb / IIIa complex with CD41 and participate in platelet aggregation. It is the most commonly used pan-platelet marker. It is used here to identify cells that are platelets and is used to phenotype platelets in combination with EAAT2 membrane protein.
[0030] refer to Figure 1According to the changes in platelet stress, more than two groups of cells are clustered in the clustering scatter plot. Further classification can classify these cells into four areas, namely Q1 area on the upper left, Q2 area on the upper right, Q3 area on the lower right, and Q4 area on the lower left: the cells in Q1 area increase sharply after changing from an unactivated state to an activated state, and there is a certain increase in the state of inhibition first and then activation; the cells in Q2 area can also be seen to increase after changing from an unactivated state to an activated state, and the increase is quite significant in the state of inhibition first and then activation. According to the test results, it is believed that: Q1 area gathers overexcited platelets with enhanced expression of EAAT2 membrane protein, Q2 area gathers stressed platelets with enhanced expression of EAAT2 membrane protein, Q3 area gathers resting (unactivated) platelets, and Q4 area gathers disintegrated platelets with sharply reduced expression of EAAT2 membrane protein. Therefore, this application uses flow cytometry to quantify four different platelet subsets marked by CD61 (pan-platelet marker) and EAAT2 membrane protein, which can intuitively present the cell phenotypes of four different stages related to the basic state and activation state of platelets: resting state (stable), stressed state (hyperactivity), overexcited state (overreaction or necrosis), and disintegration state (decay or fragmentation). According to the proportion of cells in the four zones, the condition of the individual or patient corresponding to the sample can be judged and predicted.
[0031] refer to Figure 2 The use of negative control makes the positive result more significant, which is beneficial to improve the detection sensitivity of the kit of the present application. Specifically, it can be seen that the Q1 area and the Q2 area are significantly different in the negative control and the positive control.
[0032] Using the detection method of the kit of this application, the background level (Basal) of the platelet EAAT2 membrane protein of the subject can be effectively detected and analyzed by using EAAT2 and CD61 as double labels. The EAAT2 and CD61 double labels can also be further used to analyze the distribution and proportion of different platelet subtypes related to platelet activation in the subject.
[0033] The kit of the present application may also be added with flow antibodies for other relevant markers for labeling platelets; other platelet-related markers include CD41, CD42b, CD62P, CD63 and PAC-1, etc. Among them, CD41 is also called GPIIb: integrin on the surface of platelets, involved in platelet aggregation and thrombosis; CD42b is also called GPIb: vonWillebrand factor receptor on the surface of platelets, involved in the adhesion of platelets to damaged blood vessel walls; CD62P is also called P-selectin: after activation, it is transferred from the alpha granules inside the platelets to the surface of the platelets, and participates in the adhesion and inflammatory response of platelets and leukocytes; CD63: a marker of platelet internal granules (alpha granules and dense granules), and its increased surface expression is related to platelet activation; PAC-1: an antibody that binds to active GPIIb / IIIa integrins, used to measure the aggregation state of platelets.
[0034] The kit of the present application also includes a platelet stress regulator, which includes an activator, inhibitor, interfering agent or anti-interfering agent for the platelet; the activator includes a variety of activators that can be used to activate platelets, such as arachidonic acid (AA), adenosine diphosphate (ADP), collagen (Coll), epinephrine (EPI), thrombin, thrombin receptor activating enzyme (TRAP) and lipopolysaccharide (LPS), etc.; the inhibitor includes GPRP tetrapeptide used to inhibit fibrin polymerization and prevent platelet aggregation in the activation experiment. The above stress regulators should be used to intervene or pre-treat the sample before adding EAAT2 polyclonal primary antibody and CD61-PE.
[0035] By selecting the polyclonal primary antibody Rabbit Polyclonal EAAT2 / GLT1 Antibody and secondary antibody Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa Fluor ®647Conjugate) that can specifically recognize the extracellular segment of EAAT2, and the pan-platelet marker CD61 direct antibody (CD61-PE), a flow cytometry kit that can specifically recognize the platelet EAAT2 membrane protein is provided. This kit is used to process the blood samples of the subjects, and with the help of flow cytometry detection, the intuitive results of the real-time expression of the platelet EAAT2 membrane protein of the subjects can be obtained through the flow analysis software. In addition, by observing the expression of platelet EAAT2 membrane protein and analyzing its correlation with other platelet markers under different intervention conditions, it is not only helpful to analyze the basic state of platelets, but also to evaluate the strength of platelet response to different stimuli and analyze the different subtypes and proportions of platelets.
[0036] In one possible embodiment, platelets are incubated with high concentrations of glutamate, platelet activators (such as Figure 3 Thrombin) to induce platelet function or superimpose with EAATs inhibitors (such as Figure 3 The responsiveness and regulatory potential of platelets to plasma glutamate signals and to activators can also be further assessed by pre-treating platelets with DL-TBOA (designed to block all transport channels of EAAT proteins on the platelet membrane).
[0037] Under normal circumstances, the EAATs uptake activity of resting platelets is low; when exposed to a high-concentration glutamate microenvironment, the EAATs uptake activity of platelets can be enhanced by about 2 times; when stimulated by thrombin, the immunogenicity of platelet EAATs is enhanced, and the glutamate uptake activity can be enhanced by 5 to 9 times. These results show that under different conditions, the activity of platelet EAATs in uptake of glutamate is significantly different, and the associated biological effects are also significantly different. Previous studies have found that platelet activation requires EAATs to enhance the uptake of glutamate. Given that EAAT2 dominates the uptake of glutamate by platelets, its membrane protein level can reflect the uptake activity of platelets for glutamate to a certain extent. Monitoring the expression level of platelet EAAT2 membrane protein is not only helpful in evaluating the glutamate uptake activity of platelets under different physiological and pathological conditions, but also helps to understand the real-time activation status of platelets.
[0038] The specific detection steps using the kit of this application are as follows: Blood sample collection: 2 mL of venous blood was collected in a sodium citrate anticoagulant tube, gently mixed and allowed to stand for 30 min.
[0039] Centrifugal separation of platelet-rich plasma (PRP): Isolate PRP by centrifugation at 200g for 10-15 minutes at room temperature.
[0040] Blood sample dilution: Pipette 5 μL PRP and add 95 μL platelet diluent to form a reaction system.
[0041] Pretreatment: Prepare three copies of the same sample. In the first copy, only thrombin (containing calcium) with a final concentration of 0.25~0.5IU was added to stimulate platelets for 2 min, in order to evaluate the response of platelets to thrombin stimulation through the expression of EAAT2 membrane protein. In the second copy, 4mM DL-TBOA was added to pretreat platelets for 10 min, and then thrombin (containing calcium) with a final concentration of 0.25~0.5IU was added to stimulate platelets for 2 min, in order to evaluate the response potential of platelets to thrombin stimulation through the expression of EAAT2 membrane protein. The third copy was not treated.
[0042] Staining: Add 1 μL of EAAT2 / GLT-1 antibody (primary antibody) and 1 μL of CD61-PE, incubate at room temperature in the dark for 15-30 min, then add 1 μL of EAAT2 secondary antibody - Anti-rabbit IgG (H+L), Fragment (Alexa Fluor®647 Conjugate), and continue incubating at room temperature in the dark for 15-20 min.
[0043] Fixation: Add 1 mL of fixative and fix for 30 min.
[0044] CytoFLEX flow cytometer was used for testing. Conditions: CD61 fluorescence was selected in PE channel, EAAT2 fluorescence was selected in APC channel, APC gain was between 20 and 350, PE was about 300, and compensation was adjusted appropriately according to actual conditions. If the prepared blood sample cannot be tested on the flow cytometer immediately, it should be kept away from light, stored at 4°C, and the test should be completed within 24 hours. Finally, the data was analyzed using CytExport software.
[0045] In other possible embodiments, the amount of primary antibody, secondary antibody and CD61-PE added can be adjusted within the range of 0.2~5μL according to actual needs; when it is necessary to add flow cytometry antibodies for other platelet-related markers, the amount of various antibodies added can also be adjusted within the range of 0.2~5μL according to actual needs; it should be understood that the amount of various antibodies added should be adapted to the concentration of the antibody stock solution so that the final concentration of the antibody in the reaction system reaches the preset value. Further, after testing, the final concentration reference values of various stress regulators in the reaction system are as follows: the final concentration of thrombin is 0.25~2U / mL, the final concentration of collagen (Coll) is 1~20 ug / mL, the final concentration of adenosine diphosphate (ADP) is 10~40 uM, the final concentration of thrombin receptor activating enzyme (TRAP) is 50~200 uM, and the final concentration of GPRP is 0.01~5mM.
[0046] refer to Figure 4 , the results of platelet EAAT2 membrane protein expression in a patient with AIS (Acute Ischemic Stroke) complicated with hemorrhagic transformation were summarized. By analyzing the expression of platelet EAAT2 membrane protein and its phenotypic changes on the first, second and seventh days after the patient's stroke, it was found that the inhibitory effect of DL-TBOA on its platelet aggregation function changed from weak to strong. Figure 4 The flow cytometric contour map of AI with CD61 and EAAT2 membrane proteins as the horizontal and vertical axes showed that the patient's platelets exhibited multiple activation-related phenotypes that changed over time under the basal state, when activated by thrombin, and when reactivated by thrombin after treatment with DL-TBOA.
[0047] In a possible embodiment, the CD61-PE in the kit can also help to distinguish or exclude non-reactive or weakly reactive platelet populations.
[0048] refer to Figure 5 , among which Figure 5 A-5B is a platelet flow cytometry scatter plot, which shows the expression characteristics of CD61 and EAAT2 membrane proteins in healthy human platelets under basal conditions (Basal) and thrombin-activated conditions (0.5U Thrombin). Figure 5 C-5F, according to the cell size and activation characteristics of CD61 low-fluorescence platelet subpopulation (CD61+) and CD61 high-fluorescence platelet subpopulation (CD61++), platelets can be roughly divided into three states: low activation state (CD61++, PAC-1 low / CD62P low), high activation state (CD61++, PAC-1 high / CD62P high) and weak reaction state (CD61+, PAC-1 low / CD62P low). Figure 5 Expression characteristics of EAAT2 membrane protein in CD61+ platelet subsets and CD61++ platelet subsets under G-5I-based conditions and thrombin-stimulated conditions. (* p <0.05;** p <0.01;*** p <0.001; **** p <0.0001).
[0049] Figure 5 The results showed that CD61 can be divided into two groups of platelets: CD61 low fluorescence (CD61+) and CD61 high fluorescence (CD61++). Using platelet activation markers PAC-1 and CD62P, CD61++ platelets can be further divided into low-activated platelets (CD61++, PAC-1 low / CD62P low) and high-activated platelets (CD61++, PAC-1 high / CD62P high). Before and after thrombin activation, the PAC-1 and CD62P signals of CD61+ platelets have no significant difference or only a slight increase, so it can be concluded that the CD61+ platelet group is unresponsive or weakly reactive platelets.
[0050] Based on this, it was speculated that CD61+ platelets may be composed of damaged platelets and platelet fragments. Therefore, Annxin V was further used to verify the four states of platelets. Annxin V is a Ca 2+ Annexin V expression characteristics of four platelet phenotypes using EAAT2-CD61 combined labeling.
[0051] The results are as follows Figure 6 As shown, Figure 6 A is the platelet flow density graph of the EAAT2 membrane protein negative isotype control. Figure 6 B-6C is a flow cytometry scattergram of platelets before and after thrombin activation. Figure 6 The ordinate of A-6K represents the expression level of EAAT2 membrane protein. Figure 6 The abscissa of A-6C represents the expression level of CD61. Figure 6 The abscissa of D-6K represents the expression level of Annexin V.
[0052] Platelets in the P4 region showed low expression of Annxin V, while those in P1, P2, and P3 showed high expression. Based on this, it is believed that platelets in P1~P3 are mainly platelets in the early apoptotic or necrotic state and platelet fragments, while platelets in the P4 region are mainly resting platelets. Platelets with low CD61 fluorescence (i.e., platelets in the P1 and P2 regions) increased significantly after thrombin activation and can be further divided into two phenotypes: high expression of EAAT2 and low expression of EAAT2. Considering that there are abundant EAAT2 proteins in platelets, they can only be recognized by EAAT2 membrane protein antibodies after they are located on the cell membrane surface or after the cell membrane is damaged. Based on this, it is inferred that platelets in the P1 region are necrotic platelets in which both intracellular and extracellular EAAT2 proteins are labeled after the platelet membrane is damaged; the CD61, EAAT2, and Annxin V signals of platelets in the P2 region are significantly reduced, so they may mainly be platelet debris or fragments that have lost a large amount of membrane proteins after activation.
[0053] Furthermore, the correlation between the expression of EAAT2 membrane protein and the increased expression of platelet PAC-1 was investigated. Figure 7 A is a flow cytometry plot of unactivated platelets stained with EAAT2-APC \ CD61-PE \ PAC-1-FITC \ TLR4-PC7 quadruple. Area P1 corresponds to the aforementioned resting platelets, and area P2 corresponds to the aforementioned stressed platelets. Figure 7 B is the comparison of the mean fluorescence intensity of platelet PAC-1 between P1 and P2 regions. Platelets with high CD61 fluorescence can be further divided into platelets with low EAAT2 expression (corresponding to resting platelets) and platelets with high EAAT2 expression (stressed platelets). The difference in activation levels between the two can be seen Figure 7, the fluorescence signal of PAC-1 of platelets in the P2 zone is significantly higher than that of platelets in the P1 zone. PAC-1 is used to describe the aggregation state of platelets. The higher the PAC-1 signal, the higher the activation degree of platelets. This application can accurately obtain various parameters of cells (such as target protein fluorescence signal, cell size and granularity, etc.) from different dimensions with the detection advantage of flow cytometer. The obtained data is rich and reliable, and it can also easily realize the visualization chart of multiple parameters according to actual needs. In addition, this application is simple to operate and has a short experimental cycle with the cooperation of the kit. It can not only clearly show the expression of EAAT2 membrane protein of resting platelets and activated platelets, but also flexibly add intervention groups to obtain the results after different interventions under the same experimental conditions, which greatly broadens the research space and application scope of this indicator. The experimental cycle can be completed within two hours, which can meet the clinical needs of grasping the platelet stress status of patients, is suitable for promotion and application in clinical medicine, and can be further applied to the diagnosis and treatment links related to stroke, neurodegenerative diseases, autoimmune diseases and cancer.
[0054] In summary, the present application provides a method for detecting platelet stress status using a kit, wherein the kit includes a platelet diluent, an EAAT2 polyclonal primary antibody, a flow cytometry fluorescent secondary antibody, an EAAT2 isotype control, a monoclonal antibody directly coupled to CD61 with a PE fluorescent dye, and 1% polyformaldehyde; the EAAT2 polyclonal primary antibody recognizes at least one of the amino acid sequences shown in SEQ ID No.1 to SEQ ID No.5; the detection method includes the following steps: preparing a platelet suspension using the platelet diluent; incubating the platelet suspension with the EAAT2 polyclonal primary antibody, the monoclonal antibody directly coupled to CD61 with a PE fluorescent dye, and the flow cytometry fluorescent secondary antibody in sequence; adding the polyformaldehyde to fix the sample to form a sample to be detected; detecting the specific signal of the sample by a flow cytometer; and statistically analyzing the specific signal to confirm the stress status of the sample. The method of the present application utilizes the advantages of flow cytometry and can analyze individual platelets, so that the overall stress of the platelets of the individual corresponding to the blood sample can be analyzed from a statistical perspective, providing reference data for subsequent identification and prediction of the patient's condition; and the reagents to be used in the entire flow cytometry are reasonably proportioned to form a kit, which is conducive to the unification of the detection method.
[0055] The above embodiments are preferred implementation modes of the present application, but are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present application should be equivalent replacement methods and are included in the protection scope of the present application.
Claims
1. A method for detecting platelet stress using a kit, characterized in that: The kit comprises a platelet diluent, an EAAT2 polyclonal primary antibody, a flow cytometry fluorescent secondary antibody, an EAAT2 isotype control, a monoclonal antibody directly coupled to a PE fluorescent dye with CD61, and 1% paraformaldehyde; the EAAT2 polyclonal primary antibody recognizes at least one of the amino acid sequences shown in SEQ ID No. 1 to SEQ ID No. 5; The detection method includes the following steps: preparing a platelet suspension using the platelet diluent; The platelet suspension is incubated with the EAAT2 polyclonal primary antibody, the monoclonal antibody directly coupled to the CD61 PE fluorescent dye, and the flow cytometry fluorescent secondary antibody in sequence; Adding the paraformaldehyde to fix the sample to form a sample to be detected; Detecting specific signals of the sample by flow cytometry; Statistical analysis of the specific signals confirmed the stress status of the samples.
2. The method according to claim 1, characterized in that The platelet diluent includes 10 mM HEPES, 135-145 mM NaCl, 2.6-2.8 mM KCl, 11-12 mM NaHCO3, 1-2 mM MgCl2, 0.4-0.5 mM Na2HPO4, 5-6 mM glucose, and 0.2-0.4% bovine serum albumin, and has a pH of pH7.2-pH7.
4.
3. The method according to claim 1, characterized in that The flow cytometry fluorescent secondary antibody includes a colorimetric marker derived from a goat anti-rabbit antibody that specifically recognizes the EAAT2 polyclonal primary antibody; the isotype control of the EAAT2 is a rabbit-derived IgG ISOtype.
4. The method according to claim 1, characterized in that The kit also includes other platelet-related marker antibodies, including specific antibodies for CD41, CD42b, CD62P, CD63 and / or PAC-1.
5. The method according to claim 1, characterized in that The platelet suspension is incubated in sequence with the EAAT2 polyclonal primary antibody, the monoclonal antibody directly coupled to the CD61 PE fluorescent dye, and the flow cytometry fluorescent secondary antibody, comprising: First, the platelet suspension is incubated at room temperature and away from light for 15 to 30 minutes using the EAAT2 polyclonal primary antibody and the monoclonal antibody directly coupled to the CD61 PE fluorescent dye; The platelet suspension is then incubated in the dark at room temperature for 15 to 20 minutes using the flow cytometry fluorescent secondary antibody.
6. The method according to claim 1, characterized in that The kit also includes a platelet stress regulator, which includes an activator, inhibitor, interfering agent or anti-interfering agent for the platelets; before the platelet suspension is incubated in sequence with the EAAT2 polyclonal primary antibody, the monoclonal antibody directly coupled to the CD61 PE fluorescent dye, and the flow cytometry fluorescent secondary antibody, the stress regulator is added according to the needs of statistical analysis.
7. The method according to claim 6, characterized in that The stress regulators include glutamate, arachidonic acid, adenosine diphosphate, collagen, adrenaline, thrombin, thrombin receptor activating enzyme or lipopolysaccharide as activators, excitatory amino acid transporter inhibitors as inhibitors, and inhibitors for preventing fibrin polymerization and thus blood clot formation.
8. The method according to claim 1, characterized in that The preparation method of the platelet suspension is: Freshly collected blood was anticoagulated; Centrifuge at 200 g for 10-15 min at room temperature; After the plasma is harvested, it is allowed to stand for 30 minutes to obtain platelet-rich plasma; 5 μL of the platelet-rich plasma was taken and added to 95 μL of the platelet diluent to prepare a platelet suspension.
9. The method according to claim 1, characterized in that The specific signal is associated with the relationship between the excitatory amino acid transporter 2 and platelets, and the cell analysis results of the flow cytometer are statistically analyzed to confirm the cell phenotype of platelets under different stress conditions.
Citation Information
Cited By
Method for rapidly detecting stress condition of platelets to glutamic acid
CN115979926A
Method for rapid detection of platelet stress to glutamate
CN115979926B
Reagent combination, kit and detection method for detecting platelet activation marker PAC-1
CN119147769A
Method for detecting platelet stress status using kit
WO2026016650A1
